Amgen was once again named number one among pharma peer companies, and ranked number three overall in the U.S., by patient organizations in the latest PatientView Corporate Reputation Survey, for 2024. The annual survey gathers perspectives from hundreds of patient advocacy organizations and reflects how pharmaceutical companies are perceived by the communities they serve. Amgen also maintained these rankings in the previous year’s survey.
“This recognition affirms the impact of our trusted relationships with patient advocacy groups,” said Michelle Carrillo, associate vice president of Advocacy Relations in Corporate Affairs. “It reflects our mission to serve patients and our commitment to standing alongside their communities.”
Patient groups familiar with or working directly with Amgen also awarded the company top marks in critical areas, including Integrity, Patient Centricity, Access to Medicines, Transparency in Pricing and Funding, Products of Benefit, and Long-Term Relationships.